El laboratorio farmac\u00e9utico Lilly inform\u00f3 que obtuvo la aprobaci\u00f3n de la Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios (Cofepris) para el uso de su terapia tirzepatida en M\u00e9xico para pacientes con diabetes tipo 2.La aprobaci\u00f3n del tratamiento, identificado con el nombre comercial de Mounjaro, se da un a\u00f1o despu\u00e9s que lograra el aval en los Estados Unidos, donde ya compite contra la droga Ozempik, de la danesa Novo Nordisk.<\/p>\n\n\n\n
\u201cCon esta aprobaci\u00f3n se ampl\u00edan los horizontes para el tratamiento de los 14.6 millones de adultos que viven con esta enfermedad en M\u00e9xico, seg\u00fan los datos m\u00e1s recientes de la Encuesta Nacional de Salud y Nutrici\u00f3n (ENSANUT 2022)\u201d, inform\u00f3 Lilly.<\/p>\n\n\n\n
Con esta f\u00f3rmula, la farmac\u00e9utica competir\u00e1 con la que hoy se distribuye en el mercado.<\/p>\n","protected":false},"excerpt":{"rendered":"
El laboratorio farmac\u00e9utico Lilly inform\u00f3 que obtuvo la aprobaci\u00f3n de la Comisi\u00f3n Federal para la Protecci\u00f3n contra Riesgos Sanitarios (Cofepris) para el uso de su terapia tirzepatida en M\u00e9xico para<\/p>\n","protected":false},"author":1,"featured_media":126201,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[23,21],"tags":[],"class_list":["post-126200","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-del-mundo","category-nacionales"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/formalprision.com\/wp-content\/uploads\/2024\/11\/7def57d5-cdeb-3750-a11f-edd0dbbb559e-1200x600-1.jpg","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p6id8p-wPu","_links":{"self":[{"href":"https:\/\/formalprision.com\/index.php?rest_route=\/wp\/v2\/posts\/126200","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/formalprision.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/formalprision.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/formalprision.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/formalprision.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=126200"}],"version-history":[{"count":2,"href":"https:\/\/formalprision.com\/index.php?rest_route=\/wp\/v2\/posts\/126200\/revisions"}],"predecessor-version":[{"id":126203,"href":"https:\/\/formalprision.com\/index.php?rest_route=\/wp\/v2\/posts\/126200\/revisions\/126203"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/formalprision.com\/index.php?rest_route=\/wp\/v2\/media\/126201"}],"wp:attachment":[{"href":"https:\/\/formalprision.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=126200"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/formalprision.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=126200"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/formalprision.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=126200"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}